Quantum-Si’s Customers and Researchers to Showcase Next-Generation Protein Sequencing™ at AGBT 2025

Business Wire
02-19

BRANFORD, Conn., February 18, 2025--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company, and several distinguished researchers will be presenting new research and applications at the 2025 Advances in Genome Biology and Technology (AGBT) General Meeting February 23-26th.

Quantum-Si, the pioneer in Next-Generation Protein Sequencing (NGPS™) will feature groundbreaking research through one company-led poster and two customer-led posters highlighting the transformative capabilities of NGPS in multi-omics research and drug discovery.

Scientific Posters Highlighting NGPS Innovation

Beyond the genome: Advancing our understanding of the proteome with Next-Generation Protein Sequencing

  • Presenter: Meredith Carpenter, Ph.D., Head of Scientific Affairs, Quantum-Si
  • Introduces how NGPS offers an integrated understanding of cellular processes by detecting changes at the protein level (such as post-translational modifications, or PTMs) that cannot be captured by genomics data alone.
  • February 25th, Poster 412

Integrating long-read RNAseq and Next-Generation Protein Sequencing™ to explore proteoform variability

  • Presenter: Gloria Sheynkman, Ph.D., Assistant Professor, University of Virginia
  • Demonstrates the integration of long-read RNA sequencing to capture transcript isoforms, combined with the benchtop instrument Platinum™ to produce single-molecule peptide sequencing data.
  • February 25th Poster 476

Identifying Protein Binding Partners at the Bench Using Quantum-Si

  • Presenter: Winston Timp, Ph.D., Associate Professor, BioMedical Engineering and Molecular Biology and Genetics, Johns Hopkins University
  • Demonstrates how NGPS enables direct peptide sequencing to identify protein partners regulated by genomic, epigenomic, or splicing variation, offering a rapid and cost-effective alternative to legacy technologies.
  • February 24th, Poster 465

About Quantum-Si Incorporated

Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® line of instruments enables Next-Gen Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250218012265/en/

Contacts

Investor Contact
Jeff Keyes
Chief Financial Officer
ir@quantum-si.com

Media Contact
Katherine Atkinson
SVP, Commercial Marketing
media@quantum-si.com







免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10